{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:56:35Z","timestamp":1790492195303,"version":"4.1.0"},"reference-count":69,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thrombolytic therapy might reduce venous thromboembolism\u2013related mortality and morbidity, but it could also increase the risk of major bleeding. We systematically reviewed the literature to evaluate the effectiveness and safety of thrombolytics in patients with pulmonary embolism (PE) and\/or deep venous thrombosis (DVT). We searched Medline, Embase, and Cochrane databases for relevant randomized controlled trials up to February 2019. Multiple investigators independently screened and collected data. We included 45 studies (4740 participants). Pooled estimates of PE studies indicate probable reduction in mortality with thrombolysis (risk ratio [RR], 0.61; 95% confidence interval [CI], 0.40-0.94) (moderate certainty) and possible reduction in nonfatal PE recurrence (RR, 0.56; 95% CI, 0.35-0.89) (low certainty). Pooled estimates of DVT studies indicate the possible absence of effects on mortality (RR, 0.77; 95% CI, 0.26-2.28) (low certainty) and recurrent DVT (RR, 0.99; 95% CI, 0.56-1.76) (low certainty), but possible reduction in postthrombotic syndrome (PTS) with thrombolytics (RR, 0.70; 95% CI, 0.59-0.83) (low certainty). Pooled estimates of the complete body of evidence indicate increases in major bleeding (RR, 1.89; 95% CI, 1.46-2.46) (high certainty) and a probable increase in intracranial bleeding (RR, 3.17; 95% CI 1.19-8.41) (moderate certainty) with thrombolytics. Our findings indicate that thrombolytics probably reduce mortality in patients with submassive- or intermediate-risk PE and may reduce PTS in patients with proximal DVT at the expense of a significant increase in major bleeding. Because the balance between benefits and harms is profoundly influenced by the baseline risks of critical outcomes, stakeholders involved in decision making would need to weigh these effects to define which clinical scenarios merit the use of thrombolytics.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001513","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T15:38:18Z","timestamp":1586878698000},"page":"1539-1553","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-4396","authenticated-orcid":false,"given":"Ariel","family":"Izcovich","sequence":"first","affiliation":[{"name":"Internal Medicine Service, German Hospital, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2041-1803","authenticated-orcid":false,"given":"Juan M.","family":"Criniti","sequence":"first","affiliation":[{"name":"Internal Medicine Service, German Hospital, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Popoff","sequence":"first","affiliation":[{"name":"Internal Medicine Service, German Hospital, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Lu","sequence":"first","affiliation":[{"name":"Clinical Research and Data Center, South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Oncology, Zhongshan Affiliated Hospital, Guangzhou University of Chinese Medicine, Zhongshan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ageno","sequence":"first","affiliation":[{"name":"Department of Medicine and Surgery, University of Insubria, Varese, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3930-8358","authenticated-orcid":false,"given":"Daniel M.","family":"Witt","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3772-5887","authenticated-orcid":false,"given":"Michael R.","family":"Jaff","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Schulman","sequence":"first","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, and"},{"name":"Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, ON, Canada;"},{"name":"Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0410-8089","authenticated-orcid":false,"given":"Veena","family":"Manja","sequence":"first","affiliation":[{"name":"Department of Surgery, University of California Davis, Sacramento, CA;"},{"name":"Department of Medicine, Veterans Affairs Northern California Health Care System, Mather, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Verhamme","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Sciences, Katholieke Universiteit Leuven, Leuven, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Rada","sequence":"first","affiliation":[{"name":"Epistemonikos Foundation, Santiago, Chile;"},{"name":"Department of Internal Medicine and Centro Evidencia Unversidad Cat\u00f3lica, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robby","family":"Nieuwlaat","sequence":"first","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-1650","authenticated-orcid":false,"given":"Wojtek","family":"Wiercioch","sequence":"first","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3211-8479","authenticated-orcid":false,"given":"Holger J.","family":"Sch\u00fcnemann","sequence":"first","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, and"},{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Neumann","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Centro Evidencia Unversidad Cat\u00f3lica, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,4,14]]},"reference":[{"issue":"11","key":"2020041411380952500_B1","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/ATVBAHA.114.304488","article-title":"Thrombosis: a major contributor to global disease burden","volume":"34","author":"Raskob","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020041411380952500_B2","doi-asserted-by":"crossref","first-page":"l4363","DOI":"10.1136\/bmj.l4363","article-title":"Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis","volume":"366","author":"Khan","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"2020041411380952500_B3","doi-asserted-by":"crossref","first-page":"698","DOI":"10.7326\/0003-4819-149-10-200811180-00004","article-title":"Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis","volume":"149","author":"Kahn","year":"2008","journal-title":"Ann Intern Med"},{"issue":"4","key":"2020041411380952500_B4","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1538-7836.2006.01795.x","article-title":"Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months","volume":"4","author":"Schulman","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2020041411380952500_B5","unstructured":"Higgins JPT , GreenS, eds, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. http:\/\/handbook-5-1.cochrane.org\/. Accessed 18 February 2019."},{"issue":"7","key":"2020041411380952500_B6","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"9","key":"2020041411380952500_B7","first-page":"CD004437","article-title":"Thrombolytic therapy for pulmonary embolism","volume":"9","author":"Hao","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2020041411380952500_B8","first-page":"CD002783","article-title":"Thrombolysis for acute deep vein thrombosis","volume":"11","author":"Watson","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2020041411380952500_B9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jclinepi.2011.04.015","article-title":"Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid","volume":"65","author":"Akl","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"2020041411380952500_B10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jclinepi.2017.05.005","article-title":"GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence","volume":"87","author":"Guyatt","year":"2017","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2020041411380952500_B11","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence\u2013imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2020041411380952500_B12","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence\u2013publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"2020041411380952500_B13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"2020041411380952500_B14","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/j.thromres.2009.09.017","article-title":"Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism","volume":"125","author":"Becattini","year":"2010","journal-title":"Thromb Res"},{"issue":"3","key":"2020041411380952500_B15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0735-1097(92)90002-5","article-title":"PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen Activator Italian Multicenter Study 2","volume":"20","author":"Dalla-Volta","year":"1992","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2020041411380952500_B16","first-page":"42","article-title":"Streptokinase and heparin in the treatment of pulmonary embolism: A randomized comparison","volume":"13","author":"Dotter","year":"1979","journal-title":"Vasc Endovasc Surg"},{"issue":"1","key":"2020041411380952500_B17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/MAJ.0b013e3181f1fc3e","article-title":"Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: Comparison of thrombolysis with heparin","volume":"341","author":"Fasullo","year":"2011","journal-title":"Am J Med Sci"},{"issue":"8844","key":"2020041411380952500_B18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0140-6736(93)90274-K","article-title":"Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion","volume":"341","author":"Goldhaber","year":"1993","journal-title":"Lancet"},{"issue":"3","key":"2020041411380952500_B19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF01062714","article-title":"Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial","volume":"2","author":"Jerjes-Sanchez","year":"1995","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2020041411380952500_B20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/jth.12521","article-title":"Treatment of submassive pulmonary embolism with tenecteplase or placebo: Cardiopulmonary outcomes at 3 months: Multicenter double-blind, placebo-controlled randomized trial","volume":"12","author":"Kline","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"15","key":"2020041411380952500_B21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa021274","article-title":"Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism","volume":"347","author":"Konstantinides","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"2020041411380952500_B22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCULATIONAHA.113.005544","article-title":"Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism","volume":"129","author":"Kucher","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"2020041411380952500_B23","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1378\/chest.98.6.1473","article-title":"A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism","volume":"98","author":"Levine","year":"1990","journal-title":"Chest"},{"issue":"11","key":"2020041411380952500_B24","first-page":"1288","article-title":"A study of thrombolysis and anticoagulation in patients with sub large area pulmonary embolism [in Chinese]","volume":"42","author":"Liu","year":"2013","journal-title":"Chongqing Med J"},{"issue":"3","key":"2020041411380952500_B25","first-page":"340","article-title":"Long term prognosis of thrombolytic therapy with urokinase and\/or anticoagulation submassive pulmonary embolism [in Chinese]","volume":"36","author":"Lu","year":"2008","journal-title":"Clin J Med Officer"},{"key":"2020041411380952500_B26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.0954-6820.1978.tb14909.x","article-title":"A prospective study of streptokinase and heparin in the treatment of major pulmonary embolism","volume":"203","author":"Ly","year":"1978","journal-title":"Acta Med Scand"},{"issue":"15","key":"2020041411380952500_B27","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa1302097","article-title":"Fibrinolysis for patients with intermediate-risk pulmonary embolism","volume":"370","author":"Meyer","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2020041411380952500_B28","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1378\/chest.97.3.528","article-title":"Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators","volume":"97","year":"1990","journal-title":"Chest"},{"issue":"2","key":"2020041411380952500_B29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.amjcard.2012.09.027","article-title":"Moderate pulmonary embolism treated with thrombolysis (from the \u201cMOPETT\u201d Trial)","volume":"111","author":"Sharifi","year":"2013","journal-title":"Am J Cardiol"},{"issue":"5","key":"2020041411380952500_B30","first-page":"130","article-title":"Urokinase combined with low molecular weight heparin and warfarin in the treatment of sub large area pulmonary embolism [in Chinese]","volume":"24","author":"Sun","year":"2012","journal-title":"Strait Pharm J"},{"issue":"3","key":"2020041411380952500_B31","first-page":"104","article-title":"Thrombolytic-plus-anticoagulant therapy versus anticoagulant-alone therapy in submassive pulmonary thromboembolism (TVASPE Study): A randomized clinical trial","volume":"9","author":"Taherkhani","year":"2014","journal-title":"J Tehran Heart Cent"},{"issue":"5904","key":"2020041411380952500_B32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/bmj.1.5904.343","article-title":"Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonay embolism","volume":"1","author":"Tibbutt","year":"1974","journal-title":"BMJ"},{"issue":"12","key":"2020041411380952500_B33","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1001\/jama.1970.03180120035007","article-title":"Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study","volume":"214","year":"1970","journal-title":"JAMA"},{"issue":"19","key":"2020041411380952500_B34","first-page":"1471","article-title":"Curative effect of thrombolysis and anticoagulant therapy on submassive\/intermediate risk pulmonary embolism patients [in Chinese]","volume":"32","author":"Wei","year":"2012","journal-title":"Int J Resp"},{"issue":"3","key":"2020041411380952500_B35","first-page":"69","article-title":"Low dose RT PA thrombolysis for acute sub large area pulmonary embolism: a study of 26 elderly patients [in Chinese]","volume":"52","author":"Zhang","year":"2012","journal-title":"Shandong Yiyao"},{"issue":"7","key":"2020041411380952500_B36","first-page":"897","article-title":"Analysis of therapeutic effect of urokinase combined with sequential anti-coagulation in sub-massive pulmonary embolism [in Chinese]","volume":"18","author":"Ou","year":"2012","journal-title":"J Hainan Med Coll"},{"issue":"3","key":"2020041411380952500_B37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000195517","article-title":"Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial","volume":"54","author":"Marini","year":"1989","journal-title":"Respiration"},{"issue":"4","key":"2020041411380952500_B38","first-page":"413","article-title":"Value of thrombolytic therapy for submassive pulmonary embolism patients","volume":"67","author":"Ahmed","year":"2018","journal-title":"Egypt J Chest Dis Tuberc"},{"issue":"11","key":"2020041411380952500_B39","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.15537\/smj.2018.11.22717","article-title":"Clinical efficacy of low dose recombinant tissue-type plasminogen activator for the treatment of acute intermediate-risk pulmonary embolism","volume":"39","author":"Zhang","year":"2018","journal-title":"Saudi Med J"},{"issue":"6","key":"2020041411380952500_B40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.0954-6820.1978.tb14908.x","article-title":"A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis","volume":"203","author":"Arnesen","year":"1978","journal-title":"Acta Med Scand"},{"issue":"11","key":"2020041411380952500_B41","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/000331977602701105","article-title":"Deep vein thrombosis treated with streptokinase or heparin. Follow-up of a randomized study","volume":"27","author":"Common","year":"1976","journal-title":"Angiology"},{"issue":"12","key":"2020041411380952500_B42","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/bjs.1800661203","article-title":"A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial","volume":"66","author":"Elliot","year":"1979","journal-title":"Br J Surg"},{"issue":"3","key":"2020041411380952500_B43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/ejvs.2002.1665","article-title":"Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial","volume":"24","author":"Elsharawy","year":"2002","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"9810","key":"2020041411380952500_B44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)61753-4","article-title":"Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial","volume":"379","author":"Enden","year":"2012","journal-title":"Lancet"},{"issue":"2 pt 1","key":"2020041411380952500_B45","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0002-8703(96)90427-5","article-title":"Bolus recombinant urokinase versus heparin in deep venous thrombosis: a randomized controlled trial","volume":"132","author":"Goldhaber","year":"1996","journal-title":"Am Heart J"},{"issue":"3","key":"2020041411380952500_B46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0002-9343(90)90148-7","article-title":"Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis","volume":"88","author":"Goldhaber","year":"1990","journal-title":"Am J Med"},{"issue":"5647","key":"2020041411380952500_B47","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.1.5647.806","article-title":"Treatment of deep vein thrombosis. A trial of heparin, streptokinase, and arvin","volume":"1","author":"Kakkar","year":"1969","journal-title":"BMJ"},{"issue":"7","key":"2020041411380952500_B48","first-page":"529","article-title":"Urokinase or heparin in the management of patients with deep vein thrombosis?","volume":"147","author":"Kiil","year":"1981","journal-title":"Acta Chir Scand"},{"issue":"5","key":"2020041411380952500_B49","first-page":"1018","article-title":"Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy","volume":"89","author":"Marder","year":"1977","journal-title":"J Lab Clin Med"},{"issue":"4","key":"2020041411380952500_B50","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.0954-6820.1986.tb03323.x","article-title":"Long-term sequelae of calf vein thrombosis treated with heparin or low-dose streptokinase","volume":"219","author":"Schulman","year":"1986","journal-title":"Acta Med Scand"},{"issue":"3","key":"2020041411380952500_B51","first-page":"167","article-title":"Comparative results of thrombolysis treatment with rt-PA and urokinase: a pilot study","volume":"27","author":"Schweizer","year":"1998","journal-title":"Vasa"},{"issue":"4","key":"2020041411380952500_B52","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0735-1097(00)00863-9","article-title":"Short- and long-term results after thrombolytic treatment of deep venous thrombosis","volume":"36","author":"Schweizer","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2020041411380952500_B53","first-page":"973","article-title":"Controlled study of thrombolytic therapy in deep vein thrombosis","volume":"74","author":"Tsapogas","year":"1973","journal-title":"Surgery"},{"issue":"4 suppl","key":"2020041411380952500_B54","first-page":"172S","article-title":"Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial","volume":"97","author":"Turpie","year":"1990","journal-title":"Chest"},{"issue":"6","key":"2020041411380952500_B55","first-page":"881","article-title":"Low dose systemic thrombolytic therapy for treatment of deep venous thrombosis","volume":"43","author":"Ugurlu","year":"2002","journal-title":"J Cardiovasc Surg (Torino)"},{"issue":"1","key":"2020041411380952500_B56","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0049-3848(89)90451-9","article-title":"Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and\/or pelvis","volume":"55","author":"Verhaeghe","year":"1989","journal-title":"Thromb Res"},{"issue":"23","key":"2020041411380952500_B57","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa1615066","article-title":"Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis","volume":"377","author":"Vedantham","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2020041411380952500_B58","first-page":"1509","article-title":"[Comparison of therapeutic efficacy of anticoagulation and its combination with catheter-directed thrombolysis for deep venous thrombosis of lower extremities] [in Chinese]","volume":"25","author":"Su","year":"2017","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"4","key":"2020041411380952500_B59","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"9","key":"2020041411380952500_B60","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1001\/jamainternmed.2014.3415","article-title":"Comparative outcomes of catheter-directed thrombolysis plus anticoagulation vs anticoagulation alone-treat lower-extremity proximal deep vein thrombosis","volume":"174","author":"Bashir","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2020041411380952500_B61","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2018.09.013","article-title":"Trends in catheter-directed thrombolysis and systemic thrombolysis for the treatment of pulmonary embolism","volume":"207","author":"Adusumalli","year":"2019","journal-title":"Am Heart J"},{"issue":"6","key":"2020041411380952500_B62","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jvir.2019.02.024","article-title":"Nationwide trends in use of catheter-directed therapy for treatment of pulmonary embolism in Medicare beneficiaries from 2004-2016","volume":"30","author":"Gayou","year":"2019","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"2020041411380952500_B63","doi-asserted-by":"crossref","first-page":"467","DOI":"10.5603\/CJ.a2014.0103","article-title":"Systemic or local thrombolysis in high-risk pulmonary embolism","volume":"22","author":"Macovei","year":"2015","journal-title":"Cardiol J"},{"issue":"8","key":"2020041411380952500_B64","first-page":"1101","article-title":"Thrombolysis in the treatment of lower extremity deep vein thrombosis [in Chinese]","volume":"7","author":"Gong","year":"2005","journal-title":"J Chinese Physician"},{"issue":"9","key":"2020041411380952500_B65","first-page":"1930","article-title":"A clinical study on the treatment of deep vein thrombosis of lower extremity by interventional urokinase thrombolysis via popliteal vein [in Chinese]","author":"Yu","year":"2009","journal-title":"J South Med Univ"},{"issue":"3","key":"2020041411380952500_B66","first-page":"539","article-title":"[Efficacy of regional administration of urokinase and argatroban via small saphenous vein catheter for treatment of acute deep venous thrombosis in the lower limb] [in Chinese]","volume":"31","author":"Zhou","year":"2011","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"4","key":"2020041411380952500_B67","first-page":"303","article-title":"A study of inferior vena cava filter combined with catheter directed thrombolysis in patients with deep vein thrombosis of lower extremity [in Chinese]","volume":"46","author":"Luo","year":"2011","journal-title":"Jiangxi Med J"},{"key":"2020041411380952500_B68","article-title":"Catheter-directed thrombolysis versus systemic thrombolysis in pulmonary embolism: Predictors of in-hospital mortality and major bleeding [abstract]","volume":"134","author":"Arora","year":"2016","journal-title":"Circulation"},{"key":"2020041411380952500_B69","article-title":"Catheter directed thrombolysis versus systemic thrombolysis for the treatment of pulmonary embolism [abstract]","volume":"136","author":"Geller","year":"2017","journal-title":"Circulation"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/7\/1539\/1724330\/advancesadv2020001513c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/7\/1539\/1724330\/advancesadv2020001513c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T22:46:54Z","timestamp":1696027614000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/7\/1539\/454376\/Thrombolytics-for-venous-thromboembolic-events-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,14]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001513","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,14]]}}}